About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Efficacy and Safety Study of SUNPG1622

Efficacy and Safety Study of SUNPG1622

NCT02980705·4 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Sun Pharmaceutical Industries Limited

Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Subject has provided informed written consent
Subject is ≥ 18 years of age at time of Screening
Subject must be on a stable dose of NSAID for ≥ 2 weeks prior to initiation of investigational product
Subject has a negative test for TB within 4 weeks before initiating IMP

You may not be if

Subjects with known diagnosis of fibromyalgia or complex regional pain syndromes
Active uveitis or symptomatic inflammatory bowel disease requiring therapy at screening
Radiographic evidence of total ankylosis of the spine
Subject has a planned surgical intervention between Baseline and the Week 24 evaluation for a pre-treatment condition

The record

StatusTerminated

PhasePhase 2

Taking part180

StartedNov 2017

UpdatedNov 1, 2021

Where4

SPARC Site 1
Middleburg Heights, Ohio, United States
SPARC site 3
Budapest, Hungary
SPARC site 3
Elblag, Poland